A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

Saad, Fred; M. Gleason, Donald; Murray, Robin; Tchekmedyian, S.; Venner, P.; Lacombe, Louis; L. Chin, Joseph; J. Vinholes, J.; A. Goas, J.; Chen, Bee‐Lian

doi:10.1093/jnci/94.19.1458

Public

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

Published in JNCI Journal of the National Cancer Institute • Oct 1, 2002

Authors:

Fred Saad

Donald M. Gleason

Robin Murray

Abstract

BACKGROUND: Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases. METHODS: Patients with hormone-r...

Subject

Zoledronic acid

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!